However, a multicenter clinical trial found that the AC-1204 formulation of caprylic triglyceride had no significant effect on improving functional ability or cognition among 413 patients with AD and without the APOE ɛ4 allele [172]. This evidence concerns the gene APOE and Alzheimer disease.